Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT07460362 | Recruiting Phase 2

• 1 other identifier: ML45833
• Study Type: interventional
• Target: 43
• Locations: 1 country
• Sites: 1

Brief Summary

A single-arm, open-label, multi-center clinical study of glofitamab combined with lenalidomide in high risk patients with relapsed or refractory Mantle Cell Lymphoma previously treated with a BTK Inhibitor. Patients will be eligible if they have received one or more prior lines of therapy, one of which must have been a BTKi. Patients will be enrolled according to a Simon two-stage design, with early stop criteria for lack of efficacy. Glofitamab will be administered intravenously and lenalidomide will be self-administered orally. Obinutuzumab pretreatment will be administered intravenously as 2 doses of 1000 mg prior to glofitamab initiation. The primary endpoint is BOR at the end of induction, evaluated by PET/CT according to Lugano criteria during study enrolment. The primary objective is to evaluate the best objective response rate (BOR) at the end of induction of the combination of glofitamab and lenalidomide.

Conditions

MCL; Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Keywords

Relapsed or Refractory MCL, previously treated with a BTK Inhibitor

Outcome Measures

Primary Outcomes (1)

• to evaluate the efficacy of glofitamab combined with lenalidomide in high-risk patients with R/R MCL by best overall response rate (BOR) at the end of induction.

  to evaluate the efficacy of glofitamab combined with lenalidomide in high-risk patients with R/R MCL by best overall response rate (BOR) at the end of induction, defined as the percent of patients who achieve a best complete response (CR) or partial response (PR) according to the 2014 Lugano response criteria for non-Hodgkin lymphoma at the end of induction.

  24 months

Secondary Outcomes (6)

• Objective Response Rate (ORR)

  up to 24 months

• complete response rate (CRR)

  Up to 24 months

• Duration of Response (DoR)

  Up to 48 months

• Duration of Complete Response (DoCR)

  Up to 48 months

• Progression-Free Survival (PFS)

  Up to 48 months

Other Outcomes (1)

• To evaluate the safety profiles of Glofitamab combined with lenalidomide in the treatment of high-risk mantle cell lymphoma

  48 months

Study Arms (1)

high risk patients with relapsed or refractory Mantle Cell Lymphoma previously treated with a BTKi

EXPERIMENTAL

At least one high risk features as classified: * Blastoid/pleomorphic variants ✔ Ki67 ≥50% ✔ TP53 mutation or deletion * Bulky disease (defined as any lesion ≥7.5 cm on the screening computed tomography \[CT\] scan） * Patients that did not achieve a CR with their first-line treatment * early disease progression (POD24) ✔ patients with relapse and refractory treatment above 3 lines

Drug: Glofitamab; Drug: Lenalidomide

Interventions

Glofitamab DRUG

Glofitamab is a human IgG1-bispecific antibody targeting CD20 expressed on the surface of B cells and CD3ɛ chain expressed on the surface of T cells.

high risk patients with relapsed or refractory Mantle Cell Lymphoma previously treated with a BTKi

Lenalidomide DRUG

Lenalidomide is an agent with immunomodulatory and anti-angiogenic properties which confer multiple antitumor effects.

high risk patients with relapsed or refractory Mantle Cell Lymphoma previously treated with a BTKi

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed Informed Consent Forms
• Age: \>= 18 to 80 years
• Eastern Cooperative Oncology Group =\< 2
• Diagnosis of MCL established by histologic assessment
• Previously treated with at least one prior line of systemic therapy for mantle cell lymphoma.
• Prior therapy have included a BTK inhibitor, including ibrutinib, zanubrutinib, obrutinib, acalabrutinib and various BTKi in clinical trials. BTki exposure is required, which include BTKi failure or intolerance. BTKi failure is defined as progression of disease during BTKi therapy or patients have progressed or relapsed after completing BTK inhibitor therapy
• At least one high risk features as classified:
• Blastoid/pleomorphic variants ✔ Ki67 ≥50% ✔ TP53 mutation or deletion
• Bulky disease (defined as any lesion ≥7.5 cm on the screening computed tomography \[CT\] scan）
• Patients that did not achieve a CR with their first-line treatment
• early disease progression (POD24) ✔ patients with relapse and refractory treatment above 3 lines
• Measurable lesions on cross-sectional imaging documented by diagnostic imaging(MRI, CT or PET-CT), （GTD）≥1.5 cm
• Adequate liver function : Total bilirubin =\< 3 x upper limit of normal (ULN) (unless has Gilbert's disease), Aspartate aminotransferase (AST) =\< 5.0 x ULN, Alanine aminotransferase (ALT) =\< 5.0 x ULN

You may not qualify if:

• Already enrolled in other Ongoing interventional or non-interventional R/R MCL clinical trials;
• Currently receiving immunosuppressive treatment for other diseases;
• Previous treatment with lenalidomide;
• Combined with other malignant tumors within 3 years;
• The researcher determines that they are not suitable to participate in this study;
• Serious mental or neurological disorders that affect informed consent and/or the expression or observation of adverse reactions;
• Have a history of major or extensive cardiovascular disease, such as New York Heart Association class III or Grade IV heart disease or objective assessment, myocardial infarction, unstable arrhythmia or unstable angina within 6 months before the first cycle;
• Recent major surgery (within 4 weeks before the start of the first cycle);
• Active autoimmune diseases with poor treatment control;
• Any active infection that may affect the safety of the participant, including bacterial, fungal and various viral infections, occurred within 7 days before the first day of cycle 1;
• Positive SARS-CoV-2 PCR test within 7 days prior to enrollment
• Positive test results for chronic hepatitis B infection (defined as positive hepatitis B surface antigen \[HBsAg\] serology) Participants with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if hepatitis B virus (HBV) DNA is undetectable at the time of screening. Such participants must be willing to undergo HBV DNA testing on Day 1 of every cycle and every 3 months for at least 12 months after the final cycle of study treatment and appropriate antiviral therapy as indicated.
• Positive test results for hepatitis C (hepatitis C virus \[HCV\] antibody serology testing) Participants positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
• A history of severe deep vein thrombosis event or pulmonary embolism within 6 months
• Patient follow-up was not possible.

Sponsors & Collaborators

• Peking University Third Hospital: lead

Study Sites (1)

Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China

RECRUITING

MeSH Terms

Conditions

Recurrence; Lymphoma, Mantle-Cell

Interventions

glofitamab; Lenalidomide

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Phthalimides; Phthalic Acids; Acids, Carbocyclic; Carboxylic Acids; Organic Chemicals; Piperidones; Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Isoindoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Central Study Contacts

Hongmei Jing

CONTACT

86 010-82266781; hongmei_jing@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief physician

Study Record Dates

• First Submitted: February 15, 2025
• First Posted: March 10, 2026
• Study Start: August 11, 2025
• Primary Completion (Estimated): December 30, 2027
• Study Completion (Estimated): December 30, 2029
• Last Updated: March 10, 2026

Record last verified: 2026-02

Locations

CN (1)